We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00282087
Recruitment Status : Completed
First Posted : January 25, 2006
Results First Posted : December 1, 2014
Last Update Posted : December 1, 2014
Sponsor:
Information provided by (Responsible Party):
Sarcoma Alliance for Research through Collaboration

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this trial is to study the benefits of giving chemotherapy to women after they have had surgical resection of their primary disease and have no evidence of disease remaining(known as adjuvant therapy). The major objective of this study is to determine the progression free survival. The goal is to prevent relapse or recurrence of their uterine leiomyosarcoma.

Condition or disease Intervention/treatment Phase
Leiomyosarcoma Uterine Neoplasm Drug: gemcitabine, docetaxel, doxorubicin Phase 2

Detailed Description:
Patients with a diagnosis of early-stage uterine leiomyosarcoma have a 70% chance of relapse or recurrence of their disease. Patients enrolled in this trial will receive 4 cycles of gemcitabine and docetaxel followed by 4 cycles of adriamycin. Following completion of chemotherapy, they will be have repeat imaging at regular intervals to monitor for disease recurrence along with periodic clinical evaluations.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 47 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Adjuvant Treatment of High Risk Uterine Leiomyosarcoma With Gemcitabine/Docetaxel Followed by Doxorubicin: A Phase II Trial
Study Start Date : January 2006
Actual Primary Completion Date : January 2012
Actual Study Completion Date : January 2012

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
gemcitabine/docetaxel then doxorubicin
Gemcitabine 900 mg/m2 IV over 90 minutes days 1 and 8 Docetaxel 75 mg/m2 IV day 8 (pre-medication dexamethasone 4-8 mg p.o. bid for 3 days, starting 12-24 hours prior to docetaxel). Doxorubicin 60 mg/m2 IVP every 21 days for 4 cycles (recommend use of central venous catheter access).
 Drug: gemcitabine, docetaxel, doxorubicin
Cycles = 28 days


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS [ Time Frame: Every 3 months up to two years ]

Secondary Outcome Measures :
  1. Tolerability/Toxicity of This Regimen [ Time Frame: Every 28 days during dosing and then every 3 months thereafter until patient comes off study ]
    Unacceptable toxicity is defined as grade 3 or 4 non-hematologic toxicity events that are considered to be treatment-related, excluding alopecia and fatigue.

  2. Correlation Between Age and Tumor Response to Treatment (PFS) [ Time Frame: 2 years ]
  3. Correlation Between Menopausal Status at Diagnosis and Tumor Response to Treatment (PFS) [ Time Frame: 2 years ]
  4. Correlation Between Uterine Serosal Involvement and Tumor Response to Treatment (PFS) [ Time Frame: 2 years ]
    AJCC Stage I: No serosal involvement AJCC Stage II: No serosal involement AJCC Stage III: Serosal only

  5. Correlation Between Mitotic Rate and Tumor Response to Treatment (PFS) [ Time Frame: 2 years ]
    Mitotic rate is measured in mitoses per 10 high-power fields

  6. Correlation Between Estrogen Receptor (ER) Status and Tumor Response to Treatment (PFS) [ Time Frame: 2 years ]
  7. Correlation Between Progesterone Receptor (PR) Status and Tumor Response to Treatment (PFS) [ Time Frame: 2 years ]
  8. Correlation Between 1988 FIGO Stage and Tumor Response to Treatment (PFS) [ Time Frame: 2 years ]
    Stage I: confined to the uterine corpus Stage II: confined to corpus and cervix Stage IIIA: serosa involvement only (disease could involve the uterine serosa, but patients must have had no other evidence of local spread)

  9. Correlation Between Estrogen Receptor (ER) or Progesterone Receptor (PR) Positive and Tumor Response to Treatment (PFS) [ Time Frame: 2 years ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ≥ 18 years of age
  • high risk uterine LMS, FIGO stage I or II
  • pathology review of LMS high grade and /or mitotic rate greater than or equal to 5 mitoses/10 hpf
  • no longer than 12 weeks from surgical resection of cancer
  • no evidence of residual disease
  • ECOG 0 or 1
  • ANC ≥ 1,500, hemoglobin ≥ 8.0, platelets ≥100,000
  • creatinine ≤ 1.5 x institutional upper limits of normal
  • adequate liver function
  • neuropathy (sensory and motor) ≤ CTC grade 1
  • negative pregnancy test
  • signed consent

Exclusion Criteria:

  • patients with other invasive malignancies
  • prior therapy with gemcitabine or docetaxel or doxorubicin
  • hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
  • women who are breast feeding
  • cardiac ejection fraction <50%
  • prior pelvic irradiation
  • treatment with hormone replacement or anti-hormonal agents or other cytotoxic agents
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00282087


Locations
Layout table for location information
United States, District of Columbia
Washington Cancer Institute/Washington Hospital Center (Medstar)
Washington, District of Columbia, United States, 20010
United States, Florida
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States, 33612
United States, Georgia
Winship Cancer Institute at Emory University
Atlanta, Georgia, United States, 30308
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
United States, Indiana
St. Vincent Gynecologic Oncology
Indianapolis, Indiana, United States, 46260
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 01225
Massachusetts General
Boston, Massachusetts, United States, 02114
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
United States, Nebraska
Nebraska Methodist Hospital
Omaha, Nebraska, United States, 68114
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10021
United States, Pennsylvania
Pennsylvania Oncology Hematology Associates
Philadelphia, Pennsylvania, United States, 19106
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Sarcoma Alliance for Research through Collaboration
Investigators
Layout table for investigator information
Principal Investigator: Martee L. Hensley, MD Memorial Sloan Kettering Cancer Center
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Sarcoma Alliance for Research through Collaboration
ClinicalTrials.gov Identifier: NCT00282087    
Other Study ID Numbers: SARC005
MSKCC05-128 ( Other Identifier: Memorial Sloan-Kettering Cancer Center )
First Posted: January 25, 2006    Key Record Dates
Results First Posted: December 1, 2014
Last Update Posted: December 1, 2014
Last Verified: November 2014
Keywords provided by Sarcoma Alliance for Research through Collaboration:
early stage
high grade
uterine leiomyosarcoma
adjuvant treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Leiomyosarcoma
Uterine Neoplasms
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Sarcoma
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Gemcitabine
Docetaxel
Doxorubicin
Antimetabolites, Antineoplastic
 Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors